Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Alexion Pharmaceuticals Inc

+ Add to Watchlist

ALXN:US

180.5900 USD 4.5500 2.58%

As of 20:10:00 ET on 03/27/2015.

Snapshot for Alexion Pharmaceuticals Inc (ALXN)

Open: 175.6200 Day's Range: 175.4350 - 183.0000 Volume: 1,450,673
Previous Close: 176.0400 52wk Range: 136.3700 - 203.3000 1-Yr Rtn: +20.86%

Stock Chart for ALXN

No chart data available.
  • ALXN:US 180.5900
  • 1D
  • 1M
  • 1Y
176.0400
Interactive ALXN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ALXN

Current P/E Ratio (ttm) 52.9270
Estimated P/E(12/2015) 30.6189
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) 3.4121
Est. EPS (USD) (12/2015) 5.8980
Est. PEG Ratio 1.2242
Market Cap (M USD) 36,506.00
Shares Outstanding (M) 202.15
30 Day Average Volume 1,160,414
Price/Book (mrq) 10.8865
Price/Sale (ttm) 16.0169
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/24/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ALXN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ALXN

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases. The Company develops C5 complement inhibitors and Apogens which are two classes of potential therapeutic compounds designed to selectively target specific disease-causing segments of the immune system.

Leonard Bell "Lenny"CEO/Treasurer/Co-FounderDavid L HallalChief Operating Officer
Vikas SinhaExec VP/CFOSaqib IslamExec VP/Chief Strategy Ofcr/Portfolio Mgr
More Company Profile & Key Executives for ALXN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil